Detalles de la búsqueda
1.
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
N Engl J Med
; 374(1): 54-61, 2016 Jan 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-26698910
2.
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
Proc Natl Acad Sci U S A
; 112(11): 3493-8, 2015 Mar 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-25733882
3.
Acquired resistance to crizotinib from a mutation in CD74-ROS1.
N Engl J Med
; 368(25): 2395-401, 2013 Jun 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-23724914
4.
Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors.
Proc Natl Acad Sci U S A
; 109(45): 18281-9, 2012 Nov 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-22988103
5.
SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance.
Mol Cancer Ther
; 21(1): 3-15, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34737197
6.
[Effect of plasma-derived hepatitis B vaccine 23(rd) year after a full course of vaccination in healthy young children].
Zhonghua Yu Fang Yi Xue Za Zhi
; 45(10): 920-3, 2011 Oct.
Artículo
en Zh
| MEDLINE | ID: mdl-22321594
7.
Characterization of Specific N-α-Acetyltransferase 50 (Naa50) Inhibitors Identified Using a DNA Encoded Library.
ACS Med Chem Lett
; 11(6): 1175-1184, 2020 Jun 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32550998
8.
Characterization of the CHK1 allosteric inhibitor binding site.
Biochemistry
; 48(41): 9823-30, 2009 Oct 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-19743875
9.
Narrowband Organic Light-Emitting Diodes for Fluorescence Microscopy and Calcium Imaging.
Adv Mater
; 31(42): e1903599, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31486161
10.
Application effect of rapid diagnostic techniques in pulmonary tuberculosis in Shaanxi, 2016-2020 / 中国热带医学
China Tropical Medicine
; (12): 49-2023.
Artículo
en Zh
| WPRIM | ID: wpr-976379
11.
Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497).
J Med Chem
; 61(3): 650-665, 2018 02 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29211475
12.
Controlling Synergistic Oxidation Processes for Efficient and Stable Blue Thermally Activated Delayed Fluorescence Devices.
Adv Mater
; 28(35): 7620-5, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-27337524
13.
Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance.
Nat Commun
; 7: 11384, 2016 04 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-27122193
14.
Origin of Enhanced Hole Injection in Organic Light-Emitting Diodes with an Electron-Acceptor Doping Layer: p-Type Doping or Interfacial Diffusion?
ACS Appl Mater Interfaces
; 7(22): 11965-71, 2015 Jun 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-25970499
15.
High molecular weight chitosan derivative polymeric micelles encapsulating superparamagnetic iron oxide for tumor-targeted magnetic resonance imaging.
Int J Nanomedicine
; 10: 1155-72, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25709439
16.
Engineering of an isolated p110α subunit of PI3Kα permits crystallization and provides a platform for structure-based drug design.
Protein Sci
; 23(10): 1332-40, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25043846
17.
Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.
J Med Chem
; 57(11): 4720-44, 2014 Jun 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-24819116
18.
Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib.
J Med Chem
; 57(4): 1170-87, 2014 Feb 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-24432909
19.
Identification of Cys255 in HIF-1α as a novel site for development of covalent inhibitors of HIF-1α/ARNT PasB domain protein-protein interaction.
Protein Sci
; 21(12): 1885-96, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23033253
20.
Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.
J Med Chem
; 55(18): 8091-109, 2012 Sep 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-22924734